RT Journal Article
SR Electronic
T1 A distinct symptom pattern emerges for COVID-19 Long-Haul: A nationwide study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.07.21.22277910
DO 10.1101/2022.07.21.22277910
A1 Charles A Downs
A1 Melissa D. Pinto
A1 Yong Huang
A1 Survivor Corps
A1 Sarah A. El-Azab
A1 Nathan S. Ramrakhiani
A1 Anthony Barisano
A1 Lu Yu
A1 Kaitlyn Taylor
A1 Alvaro Esperanca
A1 Heather L. Abrahim
A1 Thomas Hughes
A1 Maria Giraldo Herrera
A1 Amir M. Rahmani
A1 Nikil Dutt
A1 Rana Chakraborty
A1 Christian Mendiola
A1 Natalie Lambert
YR 2022
UL http://medrxiv.org/content/early/2022/07/22/2022.07.21.22277910.abstract
AB Long-haul COVID-19, also called Post-Acute Sequelae of SARS-CoV-2 (PASC), is a new illness caused by SARS-CoV-2 infection and characterized by the persistence of symptoms. The purpose of this cross-sectional study was to identify a distinct and significant temporal pattern of PASC symptoms (symptom type and onset) among a nationwide sample of PASC survivors (n= 5,652). The sample was randomly sorted into two independent samples for exploratory (EFA) and confirmatory factor analyses (CFA). Five factors emerged from the EFA: (1) cold & flu-like symptoms, (2) change in smell and/or taste, (3) dyspnea and chest pain, (4) cognitive & visual problems, and (5) cardiac symptoms. The CFA had excellent model fit (x2 = 513.721, df= 207, p<0.01, TLI= 0.952, CFI= 0.964, RMSEA= 0.024). These findings demonstrate a novel symptom pattern for PASC. These findings can enable nurses in the identification of at-risk patients and facilitate early, systematic symptom management strategies for PASC.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Institutional review board (IRB) approval was obtained from Indiana University.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors